Danish pharmaceutical company Novo Nordisk most valuable company in Europe thanks to Ozempic and Wegovy | Economy

LVMH is having a hard time due to disappointing sales figures. Novo is extremely popular among shareholders for its diabetes medicines Ozempic and slimming aid Wegovy. Both drugs have also been used as a weight loss aid since celebrities such as Kim Kardashian and Elon Musk recommended them on social media. The demand for Ozempic subsequently increased so quickly that a worldwide shortage of the diabetes medicine has arisen. Videos of users sharing their experiences with Ozempic and Wegovy are viewed millions of times on social media.

Novo shares are up nearly 50 percent this year. The Danish pharmaceutical company was responsible for at least 10 percent of the growth of the entire Danish economy in the first quarter of this year.

Novo has also launched a drug called Wegovy that is intended for overweight patients. The effect is almost the same as diabetes medicine Ozempic, but the dose is different. Ozempic is available on the Belgian market and is sold on prescription. Wegovy is not yet for sale in our country.

Novo Nordisk also has a Dutch branch in Alphen aan den Rijn with 150 employees.

Competitor Pfizer has also launched a new slimming product. According to a study, the drug would provide faster results than Ozempic.

ttn-3